Article

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Current opinion in HIV and AIDS (Impact Factor: 4.39). 01/2011; 6(1):80-5. DOI: 10.1097/COH.0b013e3283412515
Source: PubMed

ABSTRACT HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.
Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.
These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.

0 Followers
 · 
103 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite long-term viral suppression with antiretroviral therapy (ART), HIV persists in reservoirs and sanctuary sites. Lifelong therapy is therefore necessary, leading to problems of compliance, toxicity, and cost. Over the last few years, important advances have been made in our understanding of the composition and the maintenance mechanisms of the HIV reservoir. Although complete viral eradication is currently out of reach, a growing number of scientists think that a "functional" cure is achievable. This situation would combine no disease progression, no virus transmission, and a life expectancy close to uninfected individuals in the absence of ART. At acute HIV infection, ART increases the frequency of sustained viremia control after its discontinuation, compared with the natural history of untreated disease. For patients at the chronic stage of HIV infection, ART alone is insufficient to clear viral reservoirs and new molecules intended to purge this reservoir or gene therapy approaches are warranted. This search for a cure needs innovation, audaciousness, and coordination. It also needs political, institutional, and private commitments for funding, which by now are severely lacking.
    HIV Clinical Trials 05/2011; 12(3):121-30. DOI:10.1310/hct1203-121 · 2.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Kaposi sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) is etiologically associated with three neoplastic syndromes: Kaposi sarcoma and the uncommon HIV-associated B-cell lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman disease. The incidence of the latter B-cell pathology has been increasing in spite of antiretroviral therapy; its association with lytic virus replication has prompted interest in therapeutic strategies aimed at this phase of the virus life cycle. We designed and expressed a recombinant immunotoxin (2014-PE38) targeting the gpK8.1A viral glycoprotein expressed on the surface of the virion and infected cells. We show that this immunotoxin selectively kills KSHV-infected cells in dose-dependent fashion, resulting in major reductions of infectious virus release. The immunotoxin and ganciclovir, an inhibitor of viral DNA replication, showed marked reciprocal potentiation of antiviral activities. These results suggest that the immunotoxin, alone or in combination, may represent a new approach to treat diseases associated with KSHV lytic replication.
    mAbs 03/2012; 4(2). DOI:10.4161/mabs.4.2.19262 · 4.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-HIV immunoconjugates targeted to the HIV envelope protein may be used to eradicate the latent reservoir of HIV infection using activate-and-purge protocols. Previous studies have identified the two target epitopes most effective for the delivery of cytotoxic immunoconjugates the CD4-binding site of gp120, and the hairpin loop of gp41. Here we construct and test tetravalent double variable domain immunoglobulin molecules (DVD-Igs) that bind to both epitopes. Synthetic genes that encode DVD-Igs utilizing V-domains derived from human anti-gp120 and anti-gp41 Abs were designed and expressed in 293F cells. A series of constructs tested different inter-V-linker domains and orientations of the two V domains. Antibodies were tested for binding to recombinant Ag and native Env expressed on infected cells, for neutralization of infectious HIV, and for their ability to deliver cytotoxic immunoconjugates to infected cells. The outer V-domain was the major determinant of binding and functional activity of the DVD-Ig. Function of the inner V-domain and bifunctional binding required at least 15 AA in the inter-V-domain linker. A molecular model showing the spatial orientation of the two epitopes is consistent with this observation. Linkers that incorporated helical domains (A[EAAAK](n)A) resulted in more effective DVD-Igs than those based solely on flexible domains ([GGGGS](n)). In general, the DVD-Igs outperformed the less effective parental antibody and equaled the activity of the more effective. The ability of the DVD-Igs to deliver cytotoxic immunoconjugates in the absence of soluble CD4 was improved over that of either parent. DVD-Igs can be designed that bind to both gp120 and gp41 on the HIV envelope. DVD-Igs are effective in delivering cytotoxic immunoconjugates. The optimal design of these DVD-Igs, in which both domains are fully functional, has not yet been achieved.
    PLoS ONE 10/2012; 7(10):e46778. DOI:10.1371/journal.pone.0046778 · 3.53 Impact Factor
Show more

Preview

Download
0 Downloads
Available from